Institution-Grade Tools, Priced for Individual Investors.
Receive trading alerts directly to your inbox. Try Barchart Plus or Barchart Premier for free today.
Barchart is a leading provider of market data and services to the global financial, media, and commodity industries. From our interactive charting library, through to our leading financial analysis desktops, we connect you to the content you need.
Down almost 40% from all-time highs, Palantir stock continues to expand its customer base rapidly. Is the tech stock a buy, sell, or hold right now?
Down 54% from all-time highs, Tesla stock has underperformed the broader markets by a wide margin in 2025. Is TSLA stock a good buy right now?
Morgan Stanley recommends loading up on Tesla stock as Trump announces plans to buy brand-new Tesla vehicle in a show of support for Elon Musk.
Citigroup shares fell into bear market territory on March 10. The stock has a healthy dividend yield of 3.3% and trades at an attractive valuation.
Despite the looming headwinds, analysts remain strongly bullish on Nvidia stock and expect it to soar another 100%.
Asana stock dropped significantly following its latest quarterly report. The announcement that Asana’s CEO Dustin Moskovitz would step down created uncertainty.
The bearish case for Tesla is hard to ignore with demand for its EVs slowing and competition rising. However, the stock’s recent sharp decline has also eased concerns over its valuation.
Monday trading continued the unwinding of gains post-Trump. The S&P 500 lost 2.7%, 130 basis points away from a correction. These three Barchart Top 100 Stocks to Buy jumped 10 spots or more yesterday....
Summary Xeris Biopharmaceuticals has shown strong technical buy signals, with a 30.03% gain since the Trend Seeker buy signal on 1/28. The company offers innovative therapies like Gvoke, Keveyis, and Recorlev,...
As Nvidia strengthens its grip on the AI revolution, is its attractive valuation a sign for investors to act now?
Consumer Discretionary | -0.26% |
Information Technology | -0.38% |
Communication Services | -0.71% |
Materials | -0.81% |
Financials | -0.86% |
Utilities | -0.91% |
Energy | -0.96% |
Real Estate | -1.03% |
Health Care | -1.12% |
Consumer Staples | -1.18% |
Industrials | -1.54% |
(Sorted by Daily Weighted Alpha)
Summary Xeris Biopharmaceuticals has shown strong technical buy signals, with a 30.03% gain since the Trend Seeker buy signal on 1/28. The company offers innovative therapies like Gvoke, Keveyis, and Recorlev, and is developing XP-8121 and XeriSol/XeriJect technologies. Barchart indicators show 100% technical buy signals, a 95.32% gain in the...
Read More